ÂÜÀòÂÒÂ×

Cleidson Alves, Ph.D., has extensive work experience in research scientist roles, focusing on drug development projects and genomic biomarkers. Cleidson has worked as a Principal Scientist - Clinical Biomarker Lead at Boehringer Ingelheim since 2021, where they specialize in oncology, immunology, inflammation, and gene therapy. Prior to this, from 2017 to 2021, Cleidson worked as a Research Scientist at the University of Cologne, where they implemented technologies such as single-cell RNA-Seq and Mass Cytometry for biomarker discovery and immuno-profiling. Cleidson also has experience with sample preparation and working with human-derided primary tumor and mouse-derived samples. Cleidson has also worked as a Research Scientist at the University of Oxford and Harvard Medical School. In these roles, they conducted in vitro experiments and used various molecular and cellular techniques to unravel novel mechanisms and pathways in cancer cells. Cleidson has presented their findings at conferences and collaborated with external scientists.

Cleidson Alves - Ph.D. received their Bachelor's degree in Biology/Biological Sciences from Uniaraxá in 2005. Cleidson then pursued their Doctor of Philosophy (Ph.D.) in Cell/Cellular and Molecular Biology at USP - Universidade de São Paulo from 2006 to 2011. From 2012 to 2015, Cleidson Alves worked as a Research Fellow at Harvard University, specializing in Molecular Oncology and Molecular/Cell Biology.